EcoDrugPlus

Glutamate Ionotropic Receptor Kainate Type Subunit 1

Ensembl ID : ENSAMXG00000008675
Gene Symbol: GRIK1
3 Cross references
246 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 1

Ensembl ID : ENSAMXG00000003062
Gene Symbol: GRIK1
3 Cross references
248 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSAMXG00000001407
Gene Symbol: GRIK2
4 Cross references
197 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 3

Ensembl ID : ENSAMXG00000001749
Gene Symbol: GRIK3
2 Cross references
256 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 4

Ensembl ID : ENSAMXG00000001339
Gene Symbol: GRIK4
1 Cross references
252 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSAMXG00000014408
Gene Symbol: GRIK5
1 Cross references
291 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSAMXG00000018469
Gene Symbol: GRIK5
3 Cross references
288 Possible Orthologues:

Glutamate Metabotropic Receptor 2

Ensembl ID : ENSAMXG00000015216
Gene Symbol: GRM2
3 Cross references
211 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSAMXG00000015802
Gene Symbol: GRM4
3 Cross references
210 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSAMXG00000016591
Gene Symbol: GRM4
3 Cross references
210 Possible Orthologues:

Glutamate Receptor 1

Ensembl ID : ENSAMXG00000007424
Gene Symbol: LOC103031063
3 Cross references
250 Possible Orthologues:

Glutamate Receptor 1-Like

Ensembl ID : ENSAMXG00000007469
Gene Symbol: LOC103034619
3 Cross references
252 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).